Boehringer Ingelheim USA Corporation

The FDA granted accelerated approval to HERNEXEOS (zongertinib) in August 2025, marking the first oral therapy specifically targeting HER2 tyrosine kinase domain mutations in non-squamous NSCLC.

Boehringer Ingelheim and Re-Vana Therapeutics announced a strategic collaboration to develop extended-release ophthalmic therapies using Re-Vana's drug delivery technology that releases treatments over 6-12 months.

Avalyn Pharma secured $100 million in an oversubscribed Series D financing round to advance inhaled formulations of existing pulmonary fibrosis drugs pirfenidone and nintedanib.

BioMed X and Servier have launched the first XSeed Labs in Europe at the Spartners incubator in Paris-Saclay, implementing a crowdsourcing model that embeds academic researchers within pharmaceutical R&D facilities.

Oxford BioTherapeutics announced that Boehringer Ingelheim has selected a third drug candidate targeting OB33 to advance into IND-enabling studies under their ongoing collaboration.

The U.S. Court of Appeals for the Second Circuit affirmed dismissal of Boehringer Ingelheim's constitutional challenge to Medicare's drug price negotiation program, rejecting claims of Fifth Amendment violations and compelled speech.

Aurobindo Pharma Limited has received FDA approval for multiple generic drug formulations, including critical medications for cardiovascular, neurological, and gastrointestinal conditions.

Maxion Therapeutics has appointed Dr. Stefan Härtle as Chief Development Officer, bringing nearly 20 years of pharmaceutical R&D experience to advance the company's KnotBody® platform into clinical trials.

Solu Therapeutics has appointed Enda Moran, PhD, MBA as Chief Operating Officer to lead operational functions as the company advances its Phase 1 clinical trial of STX-0712.

D&D Pharmatech's DD01 achieved 75.8% of patients with at least 30% liver fat reduction in just 12 weeks, matching Boehringer Ingelheim's servodutide results that required 48 weeks of treatment.